Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 10/20 | 0.63 |
| ▸ | BRAF | P15056 | 6/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4922391 | 1.00 | DGAT1 (0.63) | DGAT1BRAFKDRMEN1TSHR | |
| SCHEMBL4922382 | 1.00 | DGAT1 (0.63) | DGAT1BRAFKDRMEN1TSHR | |
| SCHEMBL4924491 | 0.92 | DGAT1 (0.72) | DGAT1KDR | |
| SCHEMBL4924477 | 0.92 | DGAT1 (0.72) | DGAT1KDR | |
| SCHEMBL4924483 | 0.92 | DGAT1 (0.72) | DGAT1KDR | |
| SCHEMBL4914171 | 0.89 | DGAT1 (0.60) | DGAT1BRAFKDR | |
| SCHEMBL4914181 | 0.89 | DGAT1 (0.60) | DGAT1BRAFKDR | |
| SCHEMBL4914177 | 0.89 | DGAT1 (0.60) | DGAT1BRAFKDR | |
| SCHEMBL4923400 | 0.89 | DGAT1 (0.66) | DGAT1KDR | |
| SCHEMBL4911900 | 0.82 | DGAT1 (0.57) | DGAT1BRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064717-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES | 2008-03-13 | — | — | US | claimed |
| US-20080064717-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064717-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | DGAT1, DGAT2, DLAT | DGAT1 1/4885BRAF 4042/4885KDR 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.